Want to join the conversation?
On Sept. 30, 2015, $PFE acquired vaccines Nimenrix and Mencevax from GSK for EUR75MM (approx. $85MM) paid on the closing date and two additional installments of EUR15MM and EUR25MM to be paid in Nov. 2017 and Nov. 2018, respectively. $PFE does not expect this deal to have any significant impact on its 2015 financial performance.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.